Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 204,847 |
|
|||||
| News | - | ||||||
| Day High | 1.65 | Low High |
|||||
| Day Low | 1.54 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rallybio Holdings LLC | RLYB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 3.80% | 1.64 | 12:45:46 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.61 | 1.54 | 1.65 | 1.58 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,294 | 204,847 | $ 1.58 | $ 324,430 | - | 1.225 - 9.14 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:46:11 | 1 | $ 1.64 | USD |
Rallybio Holdings LLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 58.23M | 37.81M | - | 0 | -74.56M | -1.97 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rallybio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RLYB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.80 | 1.88 | 1.54 | 1.70 | 291,609 | -0.16 | -8.89% |
| 1 Month | 1.60 | 3.46 | 1.54 | 2.85 | 4,800,378 | 0.04 | 2.50% |
| 3 Months | 1.36 | 3.46 | 1.225 | 2.75 | 1,724,546 | 0.28 | 20.59% |
| 6 Months | 3.37 | 4.60 | 1.225 | 2.70 | 887,773 | -1.73 | -51.34% |
| 1 Year | 4.77 | 9.14 | 1.225 | 2.97 | 478,348 | -3.13 | -65.62% |
| 3 Years | 14.92 | 25.78 | 1.225 | 4.84 | 232,946 | -13.28 | -89.01% |
| 5 Years | 14.92 | 25.78 | 1.225 | 4.84 | 232,946 | -13.28 | -89.01% |
Rallybio Description
| Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. |
